03/23/2026
VANDERBILT CENTER FOR COGNITIVE MEDICINE ENROLLS FIRST DOWN SYNDROME PARTICIPANT FOR ALZHEIMERāS DISEASE STUDY
By: Danny Bonvissuto
Evan Dewey makes friends everywhere he goes. Heās buddies with the Vonlane bus drivers who transport him and his father, Brian, from his hometown of Atlanta to the Vanderbilt Center for Cognitive Medicine ā the closest enrollment site for the worldwide ABATE study that is testing a potential treatment for Alzheimerās disease in people with Down syndrome.
Evan, 42, has also made friends with Lamar Bowman, RN, and Sherri Halls, RN, at the Vanderbilt Clinical Research Center where he has his blood work done before he heads to Vanderbilt Psychiatric Hospital to receive either a placebo or an immunotherapy vaccine designed to show the body how to create antibodies against amyloid plaques, or abnormal deposits of protein in the brain that cause Alzheimerās disease. During his post-shot observation, Evan listens to music, eats lunch and chats with his friend Sarah Nelson, DNP, FNP-BC, a nurse practitioner with the Center for Cognitive Medicine.
The goal of ABATE is to see if the vaccine reduces the amyloid in the brain, with the ultimate goal of preventing Alzheimerās disease development in individuals with Down syndrome. This is the first in a series of studies Vanderbilt Health will participate in with these goals in mind.
Clinical trials related to Alzheimerās disease have been ongoing for decades, but clinical trials related to Alzheimerās disease for those with Down syndrome are new ā even though they are a high-risk population.
āIndividuals with Down syndrome are at markedly elevated risk for developing Alzheimerās disease because they have a third copy of the amyloid precursor protein gene on chromosome 21,ā said Jo Ellen Wilson, MD, PhD, MPH, associate professor of Psychiatry and Behavioral Sciences and the studyās principal investigator. āSo, from very early on in life theyāre developing much more amyloid than the non-Down syndrome community. And by the fourth decade of life, around half but perhaps even more individuals with Down syndrome will already have elevated amyloid in their brains, which is the main biologic risk factor for Alzheimerās disease.ā
To read the full article by Vanderbilt Health News online, please visit https://buff.ly/ovyFqE8